Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Management Tracks

Interim no more: Zhang assumes Overland’s CEO post; Maraganore, Ho join as advisers

Plus: Merck KGaA strategy, R&D execs; and updates from CureVac, Exo, Krystal and more

January 19, 2022 1:50 AM UTC

Ed Zhang is now CEO at Overland Pharmaceuticals, the Hillhouse-backed company he co-founded with Hua Mu in 2020 to bring innovative Western therapies to China. Zhang has served as interim CEO of the company, which has partnerships with ADC Therapeutics S.A. (NYSE:ADCT) and Allogene Therapeutics Inc. (NASDAQ:ALLO), since May 2021.

Overland also announced its appointment of John Maraganore and Peter Ho as strategic advisors. Since his retirement as CEO of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Maraganore has also joined Arch Venture Partners, Ariadne Labs, Atlas Ventures, Beam Therapeutics Inc. (NASDAQ:BEAM), Brii Biosciences Ltd. (HKEX:2137), Hemab ApS, Pictet, RTW Investments, SalioGen Therapeutics Inc., Termeer Foundation and the n-Lorem Foundation in various capacities. Ho co-founded and was president of BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160). ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article